Pramipexole is antiparkinsonian agent, dopamine receptor agonist. The mechanism of action is related to the ability of pramipexole to stimulate dopamine receptors in the striatum. This is confirmed by the effect on the level of impulses in the neurons of the striatum due to the activation of dopamine receptors in the striatum and substantia nigra.
Pramipexole may inhibit the secretion of prolactin in humans.
Treatment of Parkinson’s disease (as monotherapy and in combination with levodopa).
How to take Pramipexole
For adults the initial dose is 375 mcg / day in 3 divided doses. The dose should be increased every 5-7 days until the maximum therapeutic effect is achieved, which is observed when taking 1.5-4.5 mg / day.
In patients with impaired renal function, the initial dose is 125 μg / day, the frequency of administration is 1-3 times / day.
Maximum doses: single dose – 1.5 mg – 4.5 mg (divided into 3 doses).
It is recommended to stop treatment within 1 week.
From the side of the central nervous system and peripheral nervous system: drowsiness, dyskinesia, hallucinations; in some cases – insomnia.
From the side of digestive system: nausea, constipation.
From the side of the cardiovascular system: in some cases, at the beginning of treatment – arterial hypotension (especially with a gradual increase in the dose for too short a time).
Others: in some cases – peripheral edema.